Presented at AACFS Seventh International Conference Madison, Wisconsin, October 8-10, 2004
What is glutathione? [Refs. 1-5]
• A tripeptide composed of the amino acids glutamic acid, cysteine, and glycine. Its molecular weight is 307.33 Da.
• Found in all cells in the body, in the bile, in the epithelial lining fluid of the lungs, and, at much smaller
concentrations, in the blood.
• The predominant nonprotein thiol (molecule containing an S-H or sulfhydryl group) in cells.
• Its active form is the chemically reduced form, called “GSH.”
• GSH is compartmentalized, with concentrations ranging from 0.5 to 10 millimolar in various organs and cell types.
• GSH serves as a substrate for enzymes, including the glutathione peroxidases and the glutathione-S-transferases.
• When oxidized, two glutathione molecules join together via a disulfide bond to form “oxidized glutathione,” or “glutathione disulfide,” referred to as “GSSG.”
• Inside cells, the concentration of GSSG is normally maintained at less than 1% of total glutathione by the enzyme glutathione reductase, which is powered by NADPH, produced by the pentose phosphate shunt, part of carbohydrate metabolism.
What are some of the functions of glutathione? [Refs. 1-5]
• Maintains proper oxidation-reduction (redox) potential inside cells. Redox affects the oxidation state of sulfur in enzymes, and thus affects the rates of biochemical reactions in cells.
• Scavenges peroxides and oxidizing free radicals directly and also serves as the basis for the antioxidant network.
• Performs Phase II detoxication of heavy metals (such as mercury), organophosphate pesticides, chlorinated hydrocarbon solvents, estradiol, prostaglandins, leukotrienes, acetaminophen, and other foreign and endogenous toxins.
• Stores and transports cysteine throughout the body.
• Transports amino acids into cells, especially cystine into kidney cells.
• Regulates the cell cycle, DNA and protein synthesis and proteolysis, and gene _expression.
• Regulates signal transduction.
• Participates in bile production.
• Protects thyroid cells from self-generated hydrogen peroxide.
By means of several of the above functions, GSH plays very important roles in (1) maintaining mitochondrial function and integrity, (2) regulating cell proliferation, and (3) supporting the immune system.
How is glutathione (GSH) synthesized in the body? [Refs. 1-5]
• GSH is synthesized inside cells by a two-step process. The first step involves the ATP-powered enzyme glutamate cysteine ligase (formerly called gamma-glutamylcysteine synthetase). This step is normally the rate-limiting reaction, and is controlled by the cellular redox state and feedback inhibition, among other factors. The second step makes use of the ATP-powered enzyme glutathione synthetase.
• The necessary substrates are cysteine (which is often the rate-limiting substrate when GSH is depleted), glutamic acid (or glutamine) and glycine. Cysteine and glutamic acid are joined together in the first step, and glycine is added in the second step.
• The liver is the main producer and exporter of GSH.
• A few epithelial cell types can import GSH molecules intact.
• Most cell types use the gamma glutamyl (or GSH scavenging) cycle. This cycle makes use of the plasma-membrane-bound exoenzymes gamma-glutamyl transpeptidase and dipeptidase. This cycle disassembles GSH outside the cell and imports the parts for reassembly inside. It also serves as a transport mechanism to bring
other amino acids into the cell, cystine(di-cysteine) being favored.
Is glutathione depleted in chronic fatigue syndrome?
There is considerable evidence that it is, at least in a substantial fraction of CFS patients. Here are the results of all the published studies that bear on this question:
• GSH depletion in CFS was first suggested by Droge and Holm .
• Cheney [7,8] reported that his CFS clinical patients were almost universally low in GSH.
• Richards et al.  found that patients could be divided statistically into two distinct groups, one having significantly elevated erythrocyte GSH relative to a healthy control group, and the other having significantly lower values.
• Fulle et al.  found elevated total (reduced plus oxidized) glutathione in muscle biopsy specimens from PWCs relative to healthy controls, but they did not report values for reduced glutathione alone.
• Manuel y Keenoy et al.  found that a subgroup of fatigued patients with low magnesium, whose body stores of Mg did not improve with supplementation, had significantly lower GSH.
• Manuel y Keenoy et al.  did not find a significant difference between CFS patients and fatigued controls in terms of whole-blood GSH, but they did not compare with a healthy control group.
• Kennedy et al.  found significantly lower red blood cell GSH in PWCs compared to healthy controls (p=0.05).
• Kurup and Kurup  found significantly lower red blood cell GSH in myalgic encephalomyelitis patients compared to healthy controls (p<0.01).
In the general population, what factors or conditions are known to cause decreases in intracellular glutathione concentrations?
These factors and conditions can be divided into three groups:
• The first group is made up of those that (1) lower the rate of GSH synthesis or the rate of reduction of GSSG to GSH, or (2) raise the rate of export of GSH from cells, or (3) lead to loss of GSH from the scavenging pathway. This group includes the following: genetic defects , elevated adrenaline secretion [16-20] due to various types of stress, deficient diet  or fasting , surgical trauma [21,22], burns , and morphine .
• The second group is comprised of toxins that conjugate GSH and remove it from the body , such as organophosphate pesticides, halogenated solvents, tung oil (used on furniture), acetaminophen and some types of inhalation anesthesia.
• The third group is comprised of conditions that raise the production rates of reactive oxygen species high enough to produce oxidative stress, causing cells to export GSSG. These include strenuous or extended exercise , infections (producing leukocyte activation) , toxins that produce oxidizing free radicals during Phase I detoxication by cytochrome P450 enzymes , ionizing radiation , iron overload , and ischemia–reperfusion events (such as stroke, cardiac arrest, subarachnoid hemorrhage, and head trauma) .
Stress, distress, and stressors
• For purposes of this presentation, stressors are defined in the broad sense as events, circumstances or conditions that place demands on a person and tend to move his or her body out of allostatic balance. Allostasis is similar to homeostasis, but allows for changes in the set-point over time to match life circumstances . Stressors can be classified as physical, chemical, biological, or psychological/emotional.
• Stress is the state that results from the presentation of such demands. Selye  defined stress as “the state manifested by a specific syndrome which consists of all the nonspecifically-induced changes within a biologic system.” Although Selye emphasized the nonspecifically-induced responses, the body also exhibits specific responses that depend on the type of stress .
• Stress can be of a beneficial or a destructive nature. Distress is the destructive type of stress .
• The perceived stress that people experience depends not only on the stressors to which they are subjected, but also on “their appraisals of the situation and cognitive and emotional responses to it.” 
• A person’s history of both the occurrence of stressors and of the degree of perceived stress can be evaluated by structured interviews, and this has been done in a number of studies of CFS risk factors.
Is there evidence for higher occurrences of stressors in CFS patients prior to onset than in healthy normal controls?
YES. The types of stressors found to have higher occurrence in one or more CFS risk factor studies [34-45] include the following:
• Physical: Aerobic exercise (especially of long duration), physical trauma (especially motor vehicle accidents) and surgery (including anesthesia).
• Chemical: Exposure to toxins such as organophosphate pesticides, solvents and ciguatoxin.
• Biological: Infections, immunizations, blood transfusions, insect bites, allergic reactions, and eating or sleeping less.
Stressful life events, including death of a spouse, close family member or close friend; recent marriage; troubled or failing marriage, separation, or divorce; serious illness in immediate family; job loss, starting new job, or increased responsibility at work; and residential move.
Difficulties, including ongoing problems with relationships, persistent work problems or financial problems, mental or physical violence, overwork, extreme sustained activity, or “busyness.”
Dilemmas “A dilemma is a situation in which a person is challenged to choose between two equally undesirable alternatives.” Choosing inaction in response to a dilemma leads to further negative
Problems in childhood, including significant depression or anxiety, alcohol or other drug abuse, and/or physical violence in parents or other close family members; physical, sexual or verbal abuse, low
self-esteem and chronic tension or fighting in the family.
Is there evidence for higher perceived stress in CFS patients prior to onset, compared to healthy controls?
YES. Three studies [34, 37, 38] found that CFS patients rated their level of perceived stress prior to onset higher than did healthy, normal controls for a similar period of time.
In view of the strong correspondence between the results of the CFS risk factor studies and the known GSH depletors it is not surprising that glutathione became depleted in many CFS patients.
It appears that the CFS patients who were studied had undergone a variety of factors and conditions that are known to deplete glutathione.
How does the neuroendocrine system respond to stress?
• This system manifests both specifically- and nonspecifically-induced responses to stress . The nonspecifically-induced responses address the combined load of all the various types of stress that are being experienced simultaneously.
• The nonspecific responses are mediated by three parts of this sytem: (1) the hypothalamus-pituitary-adrenal (HPA) axis, which produces cortisol and other glucocorticoids, (2) the sympathetic-
adrenomedullary system, which produces epinephrine (adrenaline), and (3) the sympathoneural system, which produces norepinephrine (noradrenaline) .
• Rapid-onset CFS patients report that they had a normal response to stress prior to their onset of CFS. Therefore, it can be surmised that if they experienced a high load of combined long-term stress lasting a few months to several years prior to their onset, they were subject to high levels of both cortisol and adrenaline during this extended period of time.
• Note that depleted rather than elevated cortisol levels are frequently observed clinically in CFS patients (Cleare ). However, the decrease in cortisol secretion occurs later in the pathogenesis: “…the bulk of the data assembled to date is compatible with the view that the disruption in adrenocortical function is a late finding, and that elucidating the status of the central nervous system components which drive the regulation of the HPA axis would be crucial to a more complete understanding of this final event.” (Demitrack )
What are the effects of long-term elevated levels of cortisol and adrenaline on the immune system and on glutathione levels?
• Elevation of cortisol is known to suppress the inflammatory response by several mechanisms, including decreasing the _expression of cytokines and cell adhesion molecules, and decreasing the production of prostaglandins and leukotrienes . This effect is beneficially used therapeutically in many cases, but it can also have a down side if an infection is present.
• Long-term elevation of cortisol is also known to suppress cell-mediated immunity and to cause a shift to the Th2 type of immune response. Several mechanisms are involved, including suppressing the secretion of IL-1 by macrophages, inhibiting the differentiation of monocytes to macrophages, inhibiting the proliferation of T lymphocytes, and increasing the production of endonucleases, which increases the rate of apoptosis of lymphocytes [33,48].
• Long-term elevation of adrenaline can be expected to deplete GSH, because adrenaline decreases the rate of synthesis of glutathione by the liver (Estrela et al. ), increases its rate of export from the liver (Sies and Graf ; Haussinger et al. ; Estrela et al. ), and decreases the rate of reduction (recycling) of oxidized glutathione (Toleikis and Godin ).
How do viral infections arise at the onset of chronic fatigue syndrome?
I propose that glutathione depletion is the trigger for reactivation of endogenous latent viruses in CFS (hypothesis).
Here’s the support for this hypothesis:
• Most of the evidence points to reactivation of latent endogenous viruses at the onset of CFS, rather than new, primary infections (Komaroff and Buchwald )
• Infections by members of the Herpes family of viruses, such as Epstein-Barr virus and HHV-6 are commonly found in CFS patients .
• GSH depletion is associated with the activation of several types of viruses [50-53], including Herpes simplex type 1 (HSV-1) . Raising the GSH concentration inhibits replication of HSV-1 by blocking the formation of disulfide bonds in glycoprotein B, a protein that is necessary for proliferation of the virus .
• Glycoprotein B is also found in all other Herpes family viruses studied, including EBV and CMV , and very likely is present also in HHV-6 and performs the same vital function there (hypothesis).
It thus appears very likely that GSH depletion is the trigger for the reactivation of the latent forms of all the Herpes family viruses (hypothesis). Since glutathione likely becomes depleted prior to the onset of CFS, and since infections by these viruses are commonly found in CFS, it seems likely that glutathione depletion is
responsible for initiating the viral infections at the onset of CFS (hypothesis).
Can elevated cortisol and depleted glutathione explain the immune dysfunctions?
• The shift to the Th2 immune response, as observed in CFS , is a known effect of both elevated cortisol  and of depleted GSH [58, 59]. I suggest that elevated cortisol produces the Th2 shift initially, and that it is maintained later in the pathogenesis by GSH, after the cortisol level drops, due to blunting of the HPA axis.
• The following dysfunctions seen in CFS  are known effects of depleted GSH: lowered natural killer cell and cytotoxic T cell cytotoxicity; and inability of T cells to proliferate, as seen in decreased mitogen-induced proliferative response of lymphocytes and decrease in delayed-type hypersensitivity .In addition, I hypothesize the following:
• The observed chronic immune activation and the observed continuous activation of the RNase-L pathway in CFS result from the failure of cell-mediated immunity to defeat detected infections, owing to the above effects.
• The observed low molecular weight RNase-L results from lack of inhibition of caspases because of thiol (GSH) depletion, and they cleave the RNase-L. (Caspases are normally inhibited by thiols.)
• The observed elevated numbers of immune complexes result from the failure of cell-mediated immunity and the shift to the Th2 response, which produces elevated levels of antibodies.
• The observed elevation in antinuclear antibodies results from the observed higher rate of apoptosis, which is a known consequence of GSH depletion.
How does physical fatigue arise at the onset of CFS (Hypothesis)?
• When the immune system detects the viral infection, it becomes activated.
• In attempting to proliferate, the lymphocytes draw upon the already depleted supplies of GSH and its precursor, cysteine (or cystine).
• Being in the blood, the lymphocytes have earlier access to GSH and cysteine than do the skeletal muscles.
• Competition in CFS between the immune system and the skeletal muscles for these substances has already been hypothesized by Bounous and Molson , and I agree with their hypothesis.
• The skeletal muscles become more depleted in GSH.
• This produces a rise in their concentration of peroxynitrite. (Peroxynitrite forms from superoxide and nitric
oxide. Superoxide becomes elevated because the depletion of GSH causes a rise in hydrogen peroxide, and this exerts product inhibition on the superoxide dismutase reaction, causing superoxide levels to rise.)
• As Pall  has stated, “Peroxynitrite reacts with and inactivates several of the enzymes in mitochondria so that mitochondrial and energy metabolism dysfunction is one of the most important consequences of elevated peroxynitrite.”
• The resulting partial blockades in the Krebs cycles and the respiratory chains in the red, slow-twitch skeletal muscle cells decrease their rate of production of ATP. Since ATP is what powers muscle contractions, the lack of it produces physical fatigue. It becomes chronic because GSH remains depleted.
Since glutathione is at the basis of the body’s antioxidant system, its depletion can be expected to produce oxidative stress. Has this been observed in CFS?
YES. Oxidative stress is now well-established in CFS.
The following researchers have presented evidence for oxidative stress in CFS:
• Ali (1990 and 1993)
• Cheney (2000a & b)
• Richards et al. (2000a & b)
• Fulle et al. (2000)
• Manuel y Keenoy et al. (2001)
• Vecchiet et al. (2003)
• Kennedy et al. (2003)
• Smirnova and Pall (2003)
Since glutathione normally removes mercury from the body, its depletion can be expected to allow buildup of mercury in CFS patients. Is this observed?
YES. While there are no published controlled studies of mercury level testing in CFS patients, several clinicians who specialize in treating CFS have reported that many of their patients have high mercury levels:
• Ali (1995)
• Godfrey (1998)
• Conley (1998)
• Poesnecker (1999)
• Teitelbaum (2001)
• Corsello (2002)
• Goldberg (2004)
In addition, immune testing has shown significantly elevated hypersensitivity to mercury in many CFS patients (Stejskal et al., 1999; Sterzl et al., 1999; and Marcusson, 1999). This suggests that the immune system has responded to elevated mercury levels.
(Note that there have been epidemiological studies that showed no evidence that dental amalgams are associated with CFS as a causal factor. However, this does not constitute evidence that amalgams do
not give rise to elevated mercury levels after CFS onset in people who have amalgams and who may have developed CFS as a result of other causes.)
Can glutathione depletion explain autoimmnue thyroiditis in chronic fatigue syndrome?
• It is known that thyroid cells normally produce hydrogen peroxide to oxidize iodide ions as part of the pathway for producing thyroid hormones. Normally, this oxidation occurs outside the cell membrane, and the interior of the cell is protected from the hydrogen peroxide by intracellular GSH (Ekholm and Bjorkman, 1997).
• It has been shown by Duthoit et al., (2001) that if hydrogen peroxide is allowed to enter thyroid cells, it will attack and cleave thyroglobulin, producing C-terminal fragments that can diffuse into other cells and are recognized by autoantibodies from patients with autoimmune thyroid disease. This suggests that
hydrogen peroxide entry into thyroid cells may be the cause of this disease.
• It has been shown by Wikland et al. (2001), using fine needle aspiration cytology, that about 40% of patients suffering from chronic fatigue show evidence of chronic autoimmune thyroiditis, even though TSH levels were in the normal range in many of them.
• HYPOTHESIS: It seems likely that GSH depletion accounts for this high prevalence.
Why is CFS more prevalent in women than in men?
• It has been found recently that the monthly menstrual cycle in women presents an additional demand on GSH that does not occur in men. 17-beta estradiol is elevated in women from the late follicular phase through the early luteal phase of the cycle. This hormone stimulates the activity of the enzyme glutathione peroxidase
(Serviddio et al., 2002).
• Perhaps this occurs to protect against elevated production of reactive oxygen species generated during the rapid growth of the endometrium.
• The resulting reactions depress the endometrial GSH level during the time the estradiol level is high (Serviddio et al., 2002).
HYPOTHESIS: I propose that this additional demand for GSH in women exacerbates the GSH depletion that occurs as a result of other causes, and that this makes women more vulnerable to developing CFS, accounting for the higher observed prevalence of CFS in women than in men.
What approaches have been used to build glutathione?
• Diet high in sulfur-containing amino acids (as in animal-based protein, such as milk, eggs and meat) and antioxidants (as in fresh fruits and vegetables).
• Diet high in GSH, e.g. fresh fruits and vegetables and meats (Jones et al., 1992).
• N-acetylcysteine together with glutamic acid or glutamine and glycine (Clark, www.cfsn.com), or NAC together with dietary protein (Quig, 1998).
• Non-denatured whey protein (Bounous et al., 1989)
• Oral reduced glutathione (Jones et al., 1989)
• Intravenous reduced glutathione (Foster et al., 2003)
• Intramuscular reduced glutathione (Salvato, 1998)
• Transdermal reduced glutathione skin cream (www.kirkmanlabs.com)
• Sublingual reduced glutathione troches (Schaller, www.personalconsult.com; Hunjan and Evered, 1985)
• Reduced glutathione rectal suppositories (one supplier is Hopewell Pharmacy, New Jersey)
• Reduced glutathione aerosol (Buhl et al., 1990)
• Reduced glutathione nasal spray (Testa et al., 1995)
Has glutathione repletion been used clinically in CFS, and if so, what have been the results?
Patricia Salvato, M.D. has used intramuscular injections of GSH combined with ATP clinically for several years. In 1998 she reported on a study of 276 CFS patients, using 100 mg of GSH and 1 mg of ATP weekly. After 6 months of treatment, 82% experienced improvement in fatigue, 71% experienced improvement in memory and concentration, and 62% experienced improvement in levels of pain.
Paul Cheney, M.D. reported in 1999 on his clinical use of oral undenatured whey protein in CFS patients. The dosage varied with different patients, up to 40 grams per day. He reported that several of his patients improved on this treatment, and some who had had active infections with herpes family viruses, mycoplasma, or chlamydia were cleared of them by this treatment.
John S. Foster, M.D. and his colleagues reported in 2002 on their use of GSH in an intravenous fast push (over 2 to 3 minutes). Dosage ranged up to 2,500 mg, 1 or 2 times weekly, as part of a detoxification protocol used on a variety of patients, including some with CFS. They reported that the treatment has been promising
in addressing neurodegenerative and neurotoxic disorders.
Is repletion of glutathione likely to be the complete answer for treating CFS?
GSH depletion occurs near the beginning of the complex pathogenesis of CFS. There are likely to be many interactions and vicious circles as the pathogenesis develops into the pathophysiology, and there may also be damage that is difficult to correct. The mediators of such damage would likely be infections, toxins and
reactive oxygen species, all of which are able to build up because of the depletion of GSH. It is likely that a multifaceted treatment protocol will be necessary.
When GSH repletion is begun in patients who have been GSH-depleted for extended periods of time, their immune and detoxication systems can begin to function at higher levels of performance. If their bodies have accumulated elevated levels of toxins (especially mercury) and infections, glutathione repletion can cause significant Herxheimer-type reactions as pathogens are killed and toxins are mobilized. Care should be taken to proceed slowly and cautiously in such cases in order to avoid moving toxins into the central nervous
system or exacerbating symptoms to a level that is intolerable to the patient.
Glutathione depletion is an important aspect of the pathogenesis of chronic fatigue syndrome for at least a substantial fraction of patients.
(A Yahoo discussion group is now devoted to these topics. You can find it at
1. Wu, G., Fang, Y.-Z., Yang, S., Lupton, J.R., and Turner, N.D., Glutathione metabolism and its implications for health, J. Nutr. (2004) 134:489-492.
2. Dickinson, D.A., Moellering, D.R., Iles, K.E., Patel, R.P., Levonen, A.-L., Wigley, A., Darley-Usmar, V.M., and Forman, H.J., Cytoprotection against oxidative stress and the regulation of glutathione synthesis, Biol. Chem. (2003) 384:527-537.
3. Lu, S.C., Regulation of hepatic glutathione synthesis: current concepts and controversies, FASEB J. (1999) 13:1169-1183.
4. Kidd, P.M., Glutathione: systemic protectant against oxidative and free radical damage, Alt. Med. Rev. (1997) 1:155-176.
5. Lomaestro, B.M., and Malone, M., Glutathione in health and disease: pharmacotherapeutic issues, Ann. Pharmacother. (1995) 29:1263-1273.
6. Droge, W., and Holm, E., Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction, FASEB J. (1997) 11:1077-1089.
7. Cheney, P.R., Evidence of glutathione deficiency in chronic fatigue syndrome, American Biologics 11th International Symposium, Vienna, Austria, Tape no. 07-199, available from Professional Audio Recording, P.O. Box 7455, LaVerne, CA 91750 (phone 1-800-227-4473 ).
8. Cheney, P.R., Chronic fatigue syndrome, lecture presented to the CFIDS Support Group of Dallas-Fort Worth, Euless, TX, on May 15, 1999. Video tape available from Carol Sieverling, 513 Janann St., Euless, TX 76039.
9. Richards, R.S., Roberts, T.K., Dunstan, R.H., McGregor, N.R., and Butt, H.L., Free radicals in chronic fatigue syndrome: cause or effect?, Redox Report (2000) 5 (2/3):146-147.
10. Fulle, S., Mecocci, P., Fano, G., Vecchiet, I., Vecchini, A., Racciotti, D., Cherubini, A., Pizzigallo, E., Vecchiet, L., Senin, U., and Beal, M.F., Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome, Free Radical Biology and Medicine (2000) 29(12):1252-1259.
11. Manuel y Keenoy, B., Moorkens, G., Vertommen, J., Noe, M., Neve, J., and De Leeuw, I., Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium, J. Amer. Coll. Nutrition (2000) 19(3):374-382.
12. Manuel y Keenoy, B., Moorkens, G., Vertommen, J., and De Leeuw, I., Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome, Life Sciences (2001) 68:2037-2049.
13. Kennedy, G., Spence, V., McLaren, M., Hill, S., and Belch, J., Increased plasma isoprostanes and other markers of oxidative stress in chronic fatigue syndrome, abstract, Conference Syllabus, Sixth International Conference on Chronic Fatigue Syndrome, Fibromyalgia and Related Illnesses, January 30-February 2, 2003, Chantilly, VA, American Association for Chronic Fatigue Syndrome, Chicago, IL.
14. Kurup, R.K., and Kurup, P.A., Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis, Intern. J. Neurosci. (2003) 113:683-701.
15. Ristoff, E., and Larsson, A., Patients with genetic defects in the gamma-glutamyl cycle, Chemico-Biological Interactions (1998) 111-112:113-121.
16. Sies, H., and Graf, P., Hepatic thiol and glutathione efflux under the influence of vasopressin, phenylephrine and adrenaline, Biochem. J. (1985) 226:545-549.
17. Haussinger, D., Stehle, T., Gerok, W., and Sies, H., Perivascular nerve stimulation and phenylephrine responses in rat liver: metabolic effects, Ca(2+) and K(+) fluxes, Eur. J. Biochem. (1987) 163:197-203.
18. Estrela, J.M., Gil, F., Vila, J.M., and Vina, J., Alpha-adrenergic modulation of glutathione metabolism in isolated rat hepatocytes, Am. J. Physiol. (1988) 255 (Endocrinol. Metab. 18):E801-E805.
19. Toleikis, P.M., and Godin, D.V., Alteration of antioxidant status following sympathectomy: differential effects of modified plasma levels of adrenaline and noradrenaline, Molecular and Cellular Biology (1995) 152:39-49.
20. Song, Z., Cawthon, D., Beers, K., and Bottje, W.G., Hepatic and extra-hepatic stimulation of glutathione release into plasma by norepinephrine in vivo, Poultry Science (2000) 79:1632-1639.
21. Liu, P.T., Ioannides, C., Symons, A.M., and Parke, D.V., Role of tissue glutathione in prevention of surgical trauma, Xenobiotica (1993) 23(8):899-911.
22. Luo, J.-L., Hammarqvist, F., Andersson, K., and Wernerman, J., Surgical trauma decreases glutathione synthetic capacity in human skeletal muscle tissue, Am. J. Physiol. (1998) 275 (Endocrinol. Metab. 38):E359-E365.
23. Yu, Y.-M., Ryan, C.M., Fei, Z.-W., Lu, X.-M., Castillo, L., Schultz, J.T., Tompkins, R.G., and Young, V.R., Plasma L-5-oxoproline kinetics and whole blood glutathione synthesis rates in severely burned adult humans, Am. J. Physiol. Endocrinol. Metab. (2002) 282:E247-E258.
24. Roberts, S.M., Skoulis, N.P., and James, R.C., A centrally-mediated effect of morphine to diminish hepatocellular glutathione, Biochem. Pharmacol. (1987) 36(18):3001-3005.
25. Boyland, E., chapter 55 in Handbook of Experimental Pharmacology XXVIII/2 (1971) Springer Verlag, New York, pp. 584-608.
26. Ji, L.L., Oxidative stress during exercise: implication of antioxidant nutrients, Free Radical Biology & Medicine (1995) 18(6):1079-1086.
27. Bump, E.A., and Brown, J.M., Role of glutathione in the radiation response of mammalian cells in vitro and in vivo, Pharmacol. Ther. (1990) 47(1):117-36.
28. Cross, C.E., Halliwell, B., Borish, E.T., Pryor, W.A., Ames, B.N., Saul, R.L., McCord, J.M., and Harman, D., Oxygen radicals and human disease, Annals of Internal Medicine (1987) 107:526-545.
29. Panigrahi, M., Sadguna, Y., Shivakumar, B.R., Kolluri, V.R., Roy, S., Packer, L., and Ravindranath, V., Alpha-lipoic acid protects against reperfusion injury following cerebral ischemia in rats, Brain Research (1996) 717:184-188.
30. McEwen, B.S., The neurobiology of stress: from serendipity to clinical relevance, Brain Research (2000) 886(1-2):172-189.
31. Selye, H., The Stress of Life, revised edition (1978) McGraw-Hill, New York.
32. Pacek, K., and Palkovits, M., Stress and neuroendocrine responses, Endocrine Reviews (2001) 22(4):502-548.
33. Segerstrom, S.C., and Miller, G.E., Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry, Psychological Bulletin (2004) 130(4):601-630.
34. Stricklin, A., Sewell, M., and Austad, C., Objective measurement of personality variables in epidemic neuromyasthenia patients, South African Medical Journal (1990) 77:31-34.
35. Wood, G.C., Bental, R.P., Gopfert, M., Edwards, R.H., A comparative psychiatric assessment of patients with fatigue syndrome and muscle disease, Psychol. Med. (1991) 21:619-628.
36. Ware, N., Society, mind and body in chronic fatigue syndrome: an anthropological view, in Chronic Fatigue Syndrome (1993), Ciba Foundation Symposium 173, Wiley, New York.
37. Lewis, S., Cooper, C.L., and Bennett, D., Psychosocial factors and chronic fatigue syndrome, Psychological Medicine (1994) 24:661-671.
38. Dobbins, J.G., Natelson, B.H., Brassloff, I., Drastal, S., and Sisto, S.-A., Physical, behavioral, and psychological risk factors for chronic fatigue syndrome: a central role for stress?, J. of Chronic Fatigue Syndrome (1995) 1(2):43-58.
39. MacDonald, K.L., Osterholm, M.T., LeDell, K.H., White, K.E., Schenck, C.H., Chao, C.C., Persing, D.H., Johnson, R.C., Barker, J.M., and Peterson, P.K., A case-control study to assess possible triggers and cofactors in chronic fatigue syndrome, Am. J. Med. (1996) 100:548-554.
40. Salit, I.E., Precipitating factors for the chronic fatigue syndrome, J. Psychiatric Res. (1997) 31(1):59-65.
41. Theorell, T., Blomkvist, V., Lindh, G., and Evengard, B., Critical life events, infections, and symptoms during the year preceding chronic fatigue syndrome (CFS): an examination of CFS patients and subjects with a nonspecific life crisis, Psychosomatic Medicine (1999) 61:304-310.
42. Racciatti, D., Vecchiet, J., Ceccomancini, A., Ricci, F., and Pizzigallo, E., Chronic fatigue syndrome following a toxic exposure, The Science of the Total Environment (2001) 270:27-43. De Becker, P., McGregor, N., and De Meirleir, K., Possible triggers and mode of onset of chronic fatigue syndrome, J. of Chronic Fatigue Syndrome
44. Masuda, A., Munemoto, T., Yamanaka, T., Takei, M. and Tei, C., Psychosocial characteristics and immunological functions in patients with postinfectious chronic fatigue syndrome and noninfectious
chronic fatigue syndrome, J. of Behavioral Medicine (2002) 25(5):477-485.
45. Hatcher, S., and House, A., Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study, Psychological Medicine (2003) 33:1185-1192.
46. Cleare, A.J., Neuroendocrine dysfunction, chapter 16 in Handbook of Chronic Fatigue Syndrome (2003), L.A. Jason, P.A. Fennell, and R.R. Taylor, eds., Wiley, Hoboken, NJ, pp. 331-360.
47. Demitrack, M.A., Neuroendocrine correlates of chronic fatigue syndrome: a brief review, J. Psychiatric Research (1997) 31(1), 69-82.
48. Janeway, C.A., Travers, P., Walport, M. and Shlomchik, M., Immunobiology: The Immune System in Health and Disease, 5th edition (2001), Garland. New York.J
49. Komaroff, A.L., and Buchwald, D.S., Chronic fatigue syndrome: an update, Annual Reviews of Medicine (1998) 49:1-13.
50. Roederer, M., Raju, P.A., Staal, F.J.T., Herzenberg, L.A., and Herzenberg, L.A., N-acetycysteine inhibits latent HIV _expression in chronically infected cells, AIDS Research and Human Retroviruses (1991) 7:563-567.
51. Staal, F.J.T., Roederer, M., Israelski, D.M., Bubp, J., Mole, L.A., McShane, D., Deresinski, S.C., Ross, W., Sussman, H., Raju, P.A., Anderson, M.T., Moore, W., Ela, S.W., Herzenberg, L.A., and Herzenberg, L.A., Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals, AIDS Research and Human Retroviruses (1992) 8:305-311.
52. Ciriolo, M.R., Palamara, A.T., Incerpi, S., Lafavia, E., Bue, M.C., De Vito, P., Garaci, E., and Rotilio, G., Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection, J. Biol. Chem. (1997) 272(5):2700-2708.
53. Cai, J., Chen, Y., Seth, S., Furukawa, S., Compans, R.W., and Jones, D.P., Inhibition of influenza infection byh glutathione, Free Radical Biology & Medicine (2003)34(7):928-936.
54. Palamara, A.T., Perno, C.-F., Ciriolo, M.R., Dini, L., Balestra, E., D’Agostini, C., Di Francesco, P., Favalli, C., J
Rotilio, G, and Garaci, E., Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication, Antiviral Research (1995) 27:237-253.
55. Norais, N., Tang, D., Kaur, S., Chamberlain, S.H., Masiarz, F.R., Burke, R.L., and Marcus, F., Disulfide bonds of Herpes simplex virus type 2 glycoprotein gB, J. Virology (1996) 70(11):7379-7387.
56. Skowera, A., Cleare, A., Blair, D., Bevis, L., Wessely, S.C., and Peakman, M., High levels of type 2 cytokine-producing cells in chronic fatigue syndrome, Clin. Exp. Immunol. (2004) 135:294-302.
57. Elenkov, I.J., Glucocorticoids and the Th1/Th2 balance, Ann. N.Y. Acad. Sci. (2004) 1024:138-46.
58. Peterson, J.D., Herzenberg, L.A., Vasquez, K., and Waltenbaugh, C., Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns, Proc. Natl. Acad. Sci. USA (1998)
59. Murata, Y., Shimamura, T., and Hamuro, J., “The polarization of Th1/Th2 balance is dependent on the intracellular thiol redox status of macrophages due to the distinctive cytokine production, Internat. Immunol. (2002) 14(2):201-212.
60. Maher, K.J., Klimas, N.G., and Fletcher, M.A., Immunology, chapter 7 in Handbook of Chronic Fatigue Syndrome (2003), L.A. Jason, P.A. Fennell, and R.R. Taylor, eds., Wiley, Hoboken, NJ, pp. 124-151.
61. Droge, W., and Breitkreutz, R., Glutathione and immune function, Proc. Nutr. Soc. (2000) 59:595-600.
62. Suhadolnik, R.J., Peterson, D.L., O’Brien, K., Cheney, P.R., Herst, C.V.T., Reichenbach, N.L., Kon, N., Horvath, S.E., Iacono, K.T., Adelson, M.E., De Meirleir, K., De Becker, P., Charubala, R., and Pfleiderer, W., Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase-L in chronic fatigue syndrome, J. Interferon and Cytokine Research (1997) 17:377-385.
63. Vojdani, A., Ghoneum, M., Choppa, P.C., Magtoto, L., and Lapp, C.W., Elevated apoptotic cell population in patients with chronic fatigue syndrome: the pivotal role of protein kinase RNA, J. Internal Med. (1997) 242:465-478.
64. See, D.M., Cimoch, P., Chou, S., Chang, J., and Tilles, J., The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome, Integr. Physiol. Behav. Sci. (1998) 33(3):280-287.
65. Krueger, G.R., Koch, B., Hoffmann, A., Roho, J., Brandt, M.E., Wang, G., and Buja, L.M., Dynamics of chronic active herpesvirus-6 infection in patients with chronic fatigue syndrome: data acquisition for computer modeling, In Vivo (2001) 15(6):461-465.
66. Kennedy, G., Spence, V., Underwood, C., and Belch, J.J., Increased neutrophil apoptosis in chronic fatigue syndrome, J. Clin. Pathol. (2004) 57(8):891-893.
67. Bains, J.S., and Shaw, C.A., Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death, Brain Res. Brain Res. Rev. (1997) 25(3):335-358.
68. Bounous, G., and Molson, J., Competition for glutathione precursors between the immune system and the skeletal muscle: pathogenesis of chronic fatigue syndrome, Medical Hypotheses (1999) 53(4):347-349.
69. Pall, M., Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome, Medical Hypotheses (2000) 54(1):115-125.
70. Ali, M., Ascorbic acid reverses abnormal erythrocyte morphology
in chronic fatigue syndrome (abstract), Am. J. Clin. Pathol. (1990)
71. Ali, M., Hypothesis: chronic fatigue is a state of accelerated
oxidative molecular injury, J. Advancement in Medicine (1993) 6
72. Richards, R.S., Roberts, T.K., McGregor, N.R., Dunstan, R.H.,
Butt, H.L., Blood parameters indicative of oxidative stress are
associated with symptom _expression in chronic fatigue syndrome,
Redox Report (2000) 5(1):35-41.
73. Vecchiet, J., Cipollone, F., Falasca, K., Mezzetti, A.,
Pizzigallo, E., Bucciarelli, T., De Laurentis, S., Affaitati, G., De
Cesare, D., Giamberardino, M.A., Relationship between
musculoskeletal symptoms and blood markers of oxidative stress in
patients with chronic fatigue syndrome, Neuroscience Letters (2003)
74. Smirnova, I.V., and Pall, M.L., Elevated levels of protein
carbonyls in sera of chronic fatigue syndrome patients, Molecular
and Cellular Biochemistry (2003) 248:93-95.
75. Patel, R., McIntosh, L., McLaughlin, J., Brooke, S., Nimon, V.,
and Sapolsky, R., Disruptive effects of glucocorticoids on
glutathione peroxidase biochemistry in hippocampal cultures, J.
Neurochem. (2002) 82:118-125.
76. Brooks, J.C., Roberts, N., Whitehouse, G., and Majeed, T.,
Proton magnetic resonance spectroscopy and morphometry of the
hippocampus in chronic fatigue syndrome, Brit. J. Radiol. (2000)
77. Ali, M., The Canary and Chronic Fatigue (1995), Life Span Press,
Denville, NJ, p. 305.
78. Godfrey, M.E., Dental amalgam, letter to the editor, New Zealand
Medical Journal (28 Aug 1998) 111:326.
79. Conley, E.J., America Exhausted (1998), Vitality Press, Flint,
MI, p. 196.
80. Poesnecker, G.E., Chronic Fatigue Unmasked 2000 (1999),
Humanitarian Publishing Co., Quakerstown, PA, p. 210.
81. Teitelbaum, J., From Fatigued to Fantastic (2001), Penguin
Putnam, New York, p. 189.
82. Corsello, S., Review of the multiple factors (loading theory) in
the pathogenesis of chronic fatigue syndrome: theoretical review and
treatment, conference syllabus, Latest 21st Century Medical Advances
in the Diagnosis and Treatment of Fibromyalgia, Chronic Fatigue
Syndrome and Related Illnesses, Sept. 19-21, 2002, Los Angeles, CA,
Advanced Medical Conferences International, Chicago
83. Goldberg, B., and Trivieri, L., Jr., eds., Chronic Fatigue,
Fibromyalgia, and Lyme Disease, second edition (2004) Celestial
Arts, Berkeley, CA, p. 175.
84. Stejskal, V.D., Danersund, A., Lindvall, A., Hudecek, R.,
Nordman, V., Yaqob, A., Mayer, W., Bieger, W, and Lindh, U., Metal-
specific lymphocytes: biomarkers of sensitivity in man,
Neuroendocrinol. Lett. (1999) 20(5):289-298.
85. Sterzl, I., Prochazkova, J., Hrda, P., Bartova, J., Matucha, P.,
and Stejskal, V.D., Mercury and nickel allergy: risk factors in
fatigue and autoimmunity, Neuroendocrinol. Lett. (1999) 20(3-4):221-
86. Marcusson, J.A., The frequency of mercury intolerance in
patients with chronic fatigue syndrome and healthy controls, Contact
Dermatitis (1999) 41(1):60-61.
87. Yip, H.K., Li, D.K., and Yau, D.C., Int. Dent. J. (2003) 53
88. Bates, M.N., Fawcett, J., Garrett, N., Cutress, T., and
Kjellstrom, T., Health effects of dental amalgam exposure: a
retrospective cohort study, Int. J. Epidemiol. (2004) 33:1-9.
89. Ekholm, R., and Bjorkman, U., Glutathione peroxidase degrades
intracellular hydrogen peroxide and thereby inhibits intracellular
protein iodination in thyroid epithelium, Endocrinology (1997)
90. Duthoit, C., Estienne, V., Giraud, A., Durand-Gorde, J.M.,
Rasmussen, A.K., Feldt-Rasmussen, U., Carayon, P., Ruf, J., Hydrogen
peroxide-induced production of a 40 kDa immunoreactive thyroglobulin
fragment in human thyroid cells: the onset of thyroid autoimmunity?,
Biochem. J. (2001) 360(Pt 3):557-562.
91. Wikland, B., Lowhagen, T., and Sandberg, P.O., Fine-needle
aspiration cytology of the thyroid in chronic fatigue, Lancet (2001)
92. Serviddio, G., Loverro, G., Vicino, M., Prigigallo, F.,
Grattagliano, I., Altomare, E., and Vendemiale, G., Modulation of
endometrial redox balance during the menstrual cycle: relation with
sex hormones, J. Clin. Endocrinol. Metab. (2002) 87(6):2843-2848.
93. Van Konynenburg, R.A., Nutritional approaches, chapter 27 in
Handbook of Chronic Fatigue Syndrome (2003), L.A. Jason, P.A.
Fennell, and R.R. Taylor, eds., Wiley, Hoboken, NJ, pp. 580-653.
94. Jones, D.P., Coates, R.J., Flagg, E.W., Eley, J.W., Block, G.,
Greenberg, R.S., Gunter, E.W., and Jackson, B., Glutathione in foods
listed in the National Cancer Institute’s health habits and history
food frequency questionnaire, Nutrition and Cancer (1992) 17:57-75.
95. Dickinson, D.A., Iles, K.E., Zhang, H., Blank, V., and Forman,
H.J., Curcumin alters EpRE and AP-1 binding complexes and elevates
glutamate-cysteine ligase gene _expression, FASEB J. (2003) 17(3):473-
96. Clark, J. at www.cfsn.com is a proponent and supplier of this
combination (for information only, not an endorsement).
97. Quig, D., Cysteine metabolism and metal toxicity, Alternative
Medicine Review (1998) 3(4):262-270.
98. Bounous, G., and Gold, P., The biological activity of
undenatured dietary whey proteins: role of glutathione, Clin.
Invest. Med. (1991) 14(4):296-309.
99. Foster, J.S., Kane, P.C., and Speight, N., The Detoxx Book:
Detoxification of Biotoxins in Chronic Neurotoxic Syndromes,
Doctor’s Guide (2003), available from
100. Salvato, P., CFIDS patients improve with glutathione
injections, CFIDS Chronicle (Jan/Feb 1998).
101. Two suppliers are https://www.kirkmanlabs.com and
https://www.leesilsby.com (for information only, not an endorsement)
102. Schaller, J., M.D. (https://www.personalconsult.com).
103. One supplier is Hopewell Pharmacy in New Jersey (for
information only, not an endorsement).
104. Buhl, R., Vogelmeier, C., Critenden, M., Hubbard, R.C., Hoyt,
R.F., Jr., Wilson, E.M., Cantin, A.M., and Crystal, R.G.,
Augmentation of glutathione in the fluid lining the epithelium of
the lower respiratory tract by directly administering glutathione
aerosol, Proc. Natl. Acad. Sci. USA (1990) 87:4063-4067.
105. Testa, B., Mesolella, M., Testa, D., Giuliano, A., Costa, G,
Maione, F., and Iaccarino, F., Glutathione in the upper respiratory
tract, Ann. Otol. Rhinol. Laryngol. (1995) 104(2):117-119.
106. Janaky, R., Varga, V., Hermann, A., Saransaari, P., Oja, S.S.,
Mechanisms of L-cysteine neurotoxicity, Neurochem. Res. (2000) 25(9-